Deep Track Capital EXAS Position
Exited9-Fund ConvergenceDeep Track Capital exited their position in Exact Sciences Corporation (EXAS) in Q4 2025, after holding the stock for 2 quarters.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
EXAS is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Modified FOLFIRINOX in 243 days (Dec 15, 2026), making the timing of Deep Track's position particularly relevant.
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Full company profile →Short Interest
3.9%
3.2 days to cover
Deep Track Capital EXAS Position History
Frequently Asked Questions
Does Deep Track Capital own EXAS?
No. Deep Track Capital exited their position in Exact Sciences Corporation (EXAS) in Q4 2025. They previously held the stock for 2 quarters.
How many hedge funds own EXAS?
9 specialist biotech hedge funds currently hold EXAS, including Eventide Asset Management, Perceptive Advisors, Rock Springs Capital and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy EXAS?
Deep Track Capital's position in EXAS was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's EXAS position increasing or decreasing?
Deep Track Capital completely exited their EXAS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EXASCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →